Traws Pharma (TRAW) Total Non-Current Liabilities (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Total Non-Current Liabilities of $13.2 million for Q1 2026, up 2.32% year-over-year from $12.9 million in Q1 2025, and up 18.5% quarter-over-quarter from $11.1 million in Q4 2025.
Traws Pharma (TRAW) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Total Non-Current Liabilities for 15 consecutive years, with $13.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 2.32% year-over-year to $13.2 million; the TTM figure through Mar 2026 stood at $13.2 million (up 2.32% YoY), while the FY2025 annual figure was $11.1 million, down 20.94% from the prior year.
- Total Non-Current Liabilities grew to $13.2 million in Q1 2026 per TRAW's latest filing, from $11.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $14.1 million in Q4 2024 and bottomed at $7.4 million in Q2 2025.
- Historically, Total Non-Current Liabilities has averaged $11.2 million across 5 years, with a median of $11.6 million in 2023.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 33.39% — and 2025, when it plunged 41.59%.
- Traws Pharma's Total Non-Current Liabilities stood at $11.1 million in 2022, then gained by 8.57% to $12.0 million in 2023, then rose by 17.38% to $14.1 million in 2024, then declined by 20.94% to $11.1 million in 2025, then climbed by 18.5% to $13.2 million in 2026.
- Business Quant data shows TRAW's Total Non-Current Liabilities at $13.2 million in Q1 2026, $11.1 million in Q4 2025, and $7.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Traws Pharma | 5.60 Mn | 588,417.40 | - | 9.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.21 Mn |
| Dec 31, 2025 | 11.15 Mn |
| Sep 30, 2025 | 7.89 Mn |
| Jun 30, 2025 | 7.35 Mn |
| Mar 31, 2025 | 12.91 Mn |
| Dec 31, 2024 | 14.10 Mn |
| Sep 30, 2024 | 10.97 Mn |
| Jun 30, 2024 | 12.59 Mn |
| Mar 31, 2024 | 12.16 Mn |
| Dec 31, 2023 | 12.01 Mn |
| Sep 30, 2023 | 12.52 Mn |
| Jun 30, 2023 | 11.57 Mn |
| Mar 31, 2023 | 12.19 Mn |
| Dec 31, 2022 | 11.06 Mn |
| Sep 30, 2022 | 10.41 Mn |
| Jun 30, 2022 | 9.59 Mn |
| Mar 31, 2022 | 9.14 Mn |
| Dec 31, 2021 | 9.36 Mn |
| Jun 30, 2021 | 10.86 Mn |
| Mar 31, 2021 | 11.06 Mn |